FDA clears Abbott’s CardioMEMS HF system updates

Abbott has received approval from the US FDA for its CardioMEMS HF System capabilities, introducing new digital features that allow individuals to track their cardiac data directly on mobile devices. The regulatory clearance enables healthcare providers to grant US patients access to pulmonary artery pressure measurements. Heart failure is a progressive condition that prevents the heart from pumping sufficient blood, causing shortness of breath. Credit: Seacalm/Shutterstock.com. Abbott has received approval from the US Food and Drug Administration (FDA) for its CardioMEMS HF System capabilities, introducing new digital features that allow individuals to track their cardiac data directly on mobile devices.…

Source: Medical Device Network